此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

2026年9月18日 更新者:Innovent Biologics (Suzhou) Co. Ltd.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

This study is a randomized, double-blind, placebo-controlled Phase II study in participants with moderate-to-severe Sjögren's disease. Eligible participants will be randomized to receive IBI355 or placebo during the double-blind treatment period.

The study will evaluate the efficacy of IBI355 in reducing systemic disease activity and improving patient-reported symptoms and disease-related functional outcomes. Safety and tolerability will be assessed throughout the study. Pharmacokinetic, immunogenicity, pharmacodynamic, and other relevant clinical assessments will also be performed as specified in the protocol.

The results of this study are intended to characterize the efficacy and safety profile of IBI355 in participants with Sjögren's disease and to support its further clinical development.

研究类型

介入性

注册 (估计的)

198

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Anhui
      • Hefei、Anhui、中国、230001
        • The First Affiliated Hospital of University of Science and Technology of China
        • 首席研究员:
          • Xiaomei Li, M.D.
        • 接触:
        • 副研究员:
          • Zhen Tan, M.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥18 and ≤75 years.
  • Diagnosis of Sjögren's syndrome per 2016 ACR/EULAR classification criteria.
  • Duration of Sjögren's syndrome diagnosis ≤7.5 years.
  • Serum anti-Ro/SSA (Ro60 and/or Ro52) positive.
  • Stimulated whole saliva flow rate ≥0.05 mL/min at screening.
  • Baseline ESSDAI score ≥5 in ≥1 of the following domains: systemic, lymphadenopathy, glandular, articular, cutaneous, renal, hematologic, biological.
  • Stable background therapy (hydroxychloroquine ≤400 mg/day, methotrexate ≤25 mg/week, or azathioprine ≤150 mg/day) for ≥12 weeks with stable dose ≥8 weeks prior to randomization.
  • Stable oral corticosteroid dose (≤10 mg/day prednisone equivalent) for ≥4 weeks prior to randomization.

Exclusion Criteria:

  • Known hypersensitivity to IBI355 or its excipients.
  • Pregnancy or breastfeeding.
  • Uncontrolled interstitial lung disease (ILD) associated with Sjögren's syndrome (e.g., FVC <70% predicted, ClinESSDAI pulmonary domain indicating severe activity, or NYHA Class III/IV dyspnea).
  • Active or untreated latent tuberculosis (IGRA-positive without ≥1 month prophylactic treatment).
  • Chronic hepatitis B (HBsAg+), hepatitis C (HCV RNA+), HIV, or syphilis.
  • Prior use of rituximab, other anti-CD20 agents, or other biologics targeting CD40/CD40L, BAFF/APRIL, or CTLA-4 within 6 months prior to randomization.
  • Use of JAK/TYK inhibitors within 8 weeks prior to randomization.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A: IBI355 group

IBI355,IV,corresponding dose regimen according to study cohort( Part A) .

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

IBI355,IV,corresponding dose regimen according to study design

实验性的:Part B: Telitacicept 160 mg group

Participants received telitacicept 160 mg SC QW from Week 0 to Week 24. Follow-up through Week 36

Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24).

实验性的:Part A: Placebo group(IBI355-matched)

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

IBI355,IV,corresponding dose regimen according to study design

实验性的:Part B: Placebo group (Telitacicept-matched)

Participants received matching placebo SC QW from Week 0 to Week 24. Follow-up through Week 36.

Matching placebo of Talitacicept ,SC QW × 24 doses.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
大体时间:Baseline and Week 24

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement.

Baseline and Week 24

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in ESSDAI Score at Weeks 12 and 48
大体时间:Baseline to Weeks 12 and 48

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement.

Baseline to Weeks 12 and 48
Change from Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 12, 24, and 48
大体时间:Baseline to Weeks 12, 24, and 48

The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported measure assessing dryness, fatigue, and pain. Each domain is rated on a 0-to-10 numerical rating scale, and the total ESSPRI score is calculated as the mean of the three domain scores, ranging from 0 to 10. Higher scores indicate greater symptom severity. A decrease from baseline indicates improvement.

Baseline to Weeks 12, 24, and 48
Change from Baseline in Stimulated Salivary Flow (sSF) Rate at Weeks 12, 24, and 48
大体时间:Baseline to Weeks 12, 24, and 48

Stimulated salivary flow rate will be measured according to the protocol-specified procedure. An increase from baseline indicates an improvement in stimulated salivary gland function.

Baseline to Weeks 12, 24, and 48
Change from Baseline in Schirmer Test at Week 48
大体时间:Baseline to Week 48

The Schirmer test is used to assess tear production and is reported as the length of wetting of the test strip over 5 minutes, measured in millimeters (mm/5 min). Higher values indicate greater tear production.

Baseline to Week 48
Change from Baseline in Sj?gren's Tool for Assessing Response (STAR) Score at Week 48
大体时间:Baseline to Week 48

The Sj?gren's Tool for Assessing Response (STAR) is a composite assessment of treatment response in Sj?gren's disease incorporating systemic disease activity, patient-reported symptoms, and biological and glandular domains. Higher scores indicate a greater treatment response.

Baseline to Week 48
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Weeks 12, 24, and 48
大体时间:Baseline to Weeks 12, 24, and 48

The FACIT-Fatigue scale is a 13-item patient-reported measure of fatigue. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. An increase from baseline indicates improvement.

Baseline to Weeks 12, 24, and 48
Change from Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index Score at Weeks 12, 24, and 48
大体时间:Baseline to Weeks 12, 24, and 48

The EQ-5D-5L is a standardized measure of health status assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Responses are converted to an EQ-5D-5L index score using the prespecified value set, with higher index scores indicating better health status.

Baseline to Weeks 12, 24, and 48
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
大体时间:From the first dose of study intervention through Week 48

The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed throughout the study.

From the first dose of study intervention through Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月15日

初级完成 (估计的)

2027年11月1日

研究完成 (估计的)

2028年10月31日

研究注册日期

首次提交

2026年9月13日

首先提交符合 QC 标准的

2026年9月18日

首次发布 (实际的)

2026年9月23日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIBI355A201

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.